Concepedia

Frederick Haraka

FH

8

Publications

536

Citations

8

H-Index

2014

Active since

Affiliations

Ifakara Health Institute(Current)

Swiss Tropical and Public Health Institute

University of Basel

University College London

MRC Clinical Trials Unit at UCL

Frederick Haraka is an author at Ifakara Health Institute specializing in diagnostics, medicine, and tuberculosis.

Top concepts

Publications per year

2014–2024

8

Publications

8

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Conor Tweed, Rodney Dawson, Divan A. Burger et al. · The Lancet Respiratory Medicine · 2019 · 143 citations · Full text

Assessment of the novel T-cell activation marker–tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study

Damien Portevin, Félicien Moukambi, Petra Clowes et al. · The Lancet Infectious Diseases · 2014 · 136 citations

, , +8

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis

R.E. Aarnoutse, Gibson Kibiki, Klaus Reither et al. · Antimicrobial Agents and Chemotherapy · 2017 · 89 citations · Full text

Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study

Issa Sabi, Andrea Rachow, Daniel Mapamba et al. · Journal of Infection · 2018 · 70 citations

, , +7

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Müge Çevik, Lindsay C Thompson, Caryn M. Upton et al. · The Lancet Infectious Diseases · 2024 · 47 citations · Full text

Rows per page

1–5 of 8